Noticias y Actividades de Amber Therapeutics

Ver el organigrama con sus 17 ejecutivos principales

Biografías más buscadas en Amber Therapeutics

• Aidan Crawley, Chief Executive Officer
• Tiffany Le, Director
• Liliane Chamas, Director

Recientes movimientos de ejecutivos en Amber Therapeutics

• Christopher Linden, se ha incorporado a la empresa como Vice President of Engineering  (noticia publicada el 9 de junio de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en Amber Therapeutics.

Amber Therapeutics tiene 2.428 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).

Popular M&A news in Biotecnología

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado el 17 de julio de 2026).
• GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado el 15 de julio de 2026).

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Patrick Enright - Director en CuraSen Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Amber Therapeutics

• Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the US
• Amber Therapeutics - Home
• Amber Therapeutics announces successful first-in-human implants of Amber-UI - an intelligent, closed-loop bioelectrical therapy for urge and mixed urinary incontinence
• Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
• Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
• Amber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform, on which Amber’s closed-loop neuromodulation therapy for mixed urinary incontinence is being developed
• View more press releases Close

Redes sociales sobre Amber Therapeutics

• Amber Therapeutics en Wikipedia, Google News y Yahoo Finance
• Amber Therapeutics en LinkedIn, Twitter y YouTube